Analyst Price Target is $59.00
▲ +134.97% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Stoke Therapeutics in the last 3 months. The average price target is $59.00, with a high forecast of $76.00 and a low forecast of $35.00. The average price target represents a 134.97% upside from the last price of $25.11.
Current Consensus is
The current consensus among 8 investment analysts is to buy stock in Stoke Therapeutics. This Buy consensus rating has held steady for over two years.
Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. It offers a wide range of relevant tissues including the central nervous system, eye, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.